UB Fund for the School of Pharmacy and Pharmaceutical Sciences

Students in Pharmacy class in Cooke Hall.

Contribute to ongoing success by supporting school-wide initiatives through this fund.

For more than 130 years, the University at Buffalo School of Pharmacy and Pharmaceutical Sciences has been a leader in the education of pharmacists and pharmaceutical scientists. We are proud to be the leading school of pharmacy in New York State and one of the top-ranked schools in the country. 

Our outstanding faculty were responsible for some of the seminal principles in the pharmacokinetics and pharmacodynamics of drug delivery. These theoretical concepts are the building blocks for many of today’s current drug therapies and support innovative future research.

Here, you will find the unique experience of blending the intricacies of pharmacy practice with the rigors of the pharmaceutical sciences, graduating the best-trained pharmacists in the country. We provide a full range of health sciences training, giving our students a dynamic learning experience, training them to apply these skills in real-world settings, and providing them with unique strengths that they can apply to improving patient care and health outcomes.

Make a Difference Now

Other Pharmacy and Pharmaceutical Sciences Funds

News from School of Pharmacy and Pharmaceutical Sciences

  • UB Pharmacy Announces 2023 Alumni Award Winners
    7/14/23
    BUFFALO, N.Y. — The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is proud to announce the recipients of its 2023 alumni awards. Awardees will be honored at a ceremony on October 13, 2023, at the Pharmacy Building on UB’s South Campus.
  • UB Center for Integrated Global Biomedical Sciences receives NIH funding for Cloud-based Viral Surveillance Research Training Program in Jamaica
    8/9/23
    The Center for Integrated Global Biomedical Sciences at the University at Buffalo (UB), State University of New York (SUNY) has received funding to expand its Global Infectious Diseases (GID) Research Training Program. The GID is supported by the Fogarty International Center at the National Institutes of Health (NIH) for pre-doctoral and post-doctoral training that will lead to capacity building in Jamaica through UB/SUNY and the University of the West Indies (UWI) collaboration. Importantly, this new funding includes CTIS, a key cloud project implementation partner, and a women-owned small business with expertise in providing informatics solutions for clinical trials and research for over 30 years.
  • Mark J. Sinnett BS ’83, PharmD ’87: 2023 UB Distinguished Alumni Award
    8/1/23
    BUFFALO, N.Y. — Mark J. Sinnett BS ’83, PharmD ’87 is a recipient of a 2023 University at Buffalo Distinguished Alumni Award. This award is given to alumni who have made a significant impact on the university at-large and also to the programs and students at the UB School of Pharmacy and Pharmaceutical Sciences (SPPS).
  • Balu-Iyer awarded $1.5 million NHLBI/NIH grant to develop hemophilia treatment
    6/9/23

    EDI, CBLS awards provide additional $850K to UB School of Pharmacy and Pharmaceutical Sciences.

  • Meaney named ACCP Fellow
    8/14/23
    Calvin Meaney, PharmD, clinical associate professor and interim division head, Division of Outcomes and Practice Advancement, Department of Pharmacy Practice, has been named a Fellow of the American College of Clinical Pharmacy (ACCP).
  • First Hempling McGlynn Endowed Chair Named
    12/13/21

    Mary B. Riedy will implement an innovative teaching and research program that will merge disciplines of pharmacy, genetics and pediatrics.
     

  • UB CIGBS Announces Stop Diabetes Progression, a New Global Community Health Site Initiative
    10/18/23
    The University at Buffalo (UB) Center for Integrated Global Biomedical Sciences (CIGBS) has announced plans to launch, Stop Diabetes Progression, a new health initiative, focusing on the creation of community-based education networks in Western New York, Jamaica and Zimbabwe to engage individuals with pre-diabetes and those with an established diagnosis of diabetes mellitus. The goal of this new initiative is to stop the progression of the disease for both groups.